Warning: fopen(/home/virtual/enm-kes/journal/upload/ip_log/ip_log_2026-03.txt): failed to open stream: Permission denied in /home/virtual/lib/view_data.php on line 100 Warning: fwrite() expects parameter 1 to be resource, boolean given in /home/virtual/lib/view_data.php on line 101 Association between Serum Fibroblast Growth Factor 21 Levels and Bone Mineral Density in Postmenopausal Women
Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search
Advanced Search
mobile menu button

Articles

Page Path
HOME > Endocrinol Metab > Volume 33(2); 2018 > Article
Original Article
Association between Serum Fibroblast Growth Factor 21 Levels and Bone Mineral Density in Postmenopausal Women
Hoon Sung Choi1, Hyang Ah Lee2, Sang-Wook Kim1, Eun-Hee Cho1orcid
Endocrinology and Metabolism 2018;33(2):273-277.
DOI: https://doi.org/10.3803/EnM.2018.33.2.273
Published online: June 21, 2018

1Department of Internal Medicine, Kangwon National University School of Medicine, Chuncheon, Korea.

2Department of Obstetrics and Gynecology, Kangwon National University School of Medicine, Chuncheon, Korea.

Corresponding author: Eun-Hee Cho. Department of Internal Medicine, Kangwon National University Hospital, Kangwon National University School of Medicine, 156 Baengnyeong-ro, Chuncheon 24289, Korea. Tel: +82-33-258-9167, Fax: +82-33-258-2455, ehcho@kangwon.ac.kr
• Received: February 19, 2018   • Revised: April 8, 2018   • Accepted: April 12, 2018

Copyright © 2018 Korean Endocrine Society

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 6,404 Views
  • 57 Download
  • 10 Web of Science
  • 8 Crossref
  • 11 Scopus
prev next
Full Article

Download PDF Download PDF

  • Background
    Despite the beneficial effect of fibroblast growth factor 21 (FGF21) on metabolic disease, there are concerns about adverse effects on bone metabolism, supported by animal studies. However, a recent human study showed the positive association between serum FGF21 level and bone mineral density (BMD) in healthy premenopausal women. We undertook this study to examine the association between FGF21 level and BMD in healthy postmenopausal Korean women who are susceptible to osteoporosis.
  • Methods
    We used data of 115 participants from a cohort of healthy postmenopausal women (>50 years old) to examine the association between serum FGF21 level and BMD. The clinical characteristics were obtained from the participants, and blood testing and serum FGF21 testing were undertaken. BMD of the lumbar spine, femoral neck and total hip area, and bone markers were used in the analyses.
  • Results
    The mean age of the participants was 60.2±7.2 years. Serum FGF21 levels showed negative correlation with BMD and T-scores in all three areas, but there were no statistically significant differences. Multivariate analyses with adjustment for age and body mass index also did not show significant association between serum FGF21 level and BMD. In addition, serum FGF21 level also showed no correlation with osteocalcin and C-telopeptide levels.
  • Conclusion
    In our study, serum FGF21 level showed no significant correlation with BMD and T-scores.
  • Keywords: Fibroblast growth factor 21; Postmenopausal women; Bone density; Osteoporosis
Fibroblast growth factor 21 (FGF21) is a metabolic hormone that is expressed mainly in the liver to maintain homeostasis [1]. High level of circulating FGF21 is known to be induced by many metabolic disorders, such as type 2 diabetes, obesity, chronic kidney disease, non-alcoholic fatty liver disease, and cardiovascular diseases [2345]. Recently, Markan et al. [6] demonstrated that the serum FGF21 is produced from the liver, and not from adipose tissue.
In animals, both transgenic and pharmacologic FGF21 gain of function resulted in significant bone loss by augmenting the effects of peroxisome proliferator-activated receptor γ (PPAR-γ) along with diminished osteoblastic activity and increased osteoclastic activity [7]. However, in human studies, there was an independent positive association between plasma FGF21 levels and bone mineral density (BMD) in 24 healthy young women, but not men [8], suggesting a paradoxical response in mice and humans.
Recently, another study demonstrated that mice treated with recombinant human FGF21 showed no bone loss on dual-energy X-ray absorptiometry (DXA) scan and FGF21 knockout mice also did not show high bone mass [9], suggesting a neutral effect of FGF21 on bone metabolism. In another human study regarding FGF21 and BMD in 168 Han Chinese adults, plasma FGF21 concentrations were negatively correlated with BMD in the femoral neck, but there was an inverse association between only Ward's triangle BMD and plasma FGF21 in 119 women, except for the femoral neck and spine BMD [10].
However, the association between plasma FGF21 concentrations and BMD in human studies is controversial. Therefore, here, we evaluated the association between plasma FGF21 levels and BMD in healthy postmenopausal women in Korea.
Subjects
Our study included a previously formed cohort of 337 healthy postmenopausal women volunteers older than 50 years, from June 2009 to October 2009 in Kangwon National University Hospital [11]. Serum FGF21 levels were measured from 115 consecutively selected subjects, who were not different from the unselected subjects in terms of clinical characteristics. Menopause was defined as the absence of menstruation for at least 1 year. Exclusion criteria for this study were women taking glucocorticoids and estrogen for longer than the preceding 3 months or women with diseases that could affect bone metabolism, such as Graves' disease or Cushing syndrome, hysterectomized women, and premenopausal bilaterally ovariectomized women. The study protocol was approved by the Institutional Review Board of Kangwon National University Hospital (IRB number 09-07). Written informed consent was obtained from each participant.
Laboratory tests
Areal BMD (g/cm2) values were determined in the spine, femoral neck, and total hip in all subjects using a Lunar Prodigy Vision DXA system (Lunar Corp., Madison, WI, USA). Osteoporosis was determined as a T-score ≤−2.5 standard deviations at any site according to the definition of World Health Organization. Single investigator performed all densitometry tests and analyses in all subjects. Participants' blood samples were collected during fasting for at least 6 hours after breakfast. Serum FGF21 concentration was measured using human FGF21 Quantikine ELISA Kit (R&D Systems, Minneapolis, MN, USA) with a coefficient of variation of 2.9% to 3.9% (intra-assay) and 5.2% to 10.9% (inter-assay).
Statistical analyses
The correlation between FGF21 concentration and other continuous variables was evaluated using Pearson correlation analysis. In the analysis of bone mass, actual BMD values were used, not T-scores or Z-scores. Multivariate analyses were performed with adjustment for age, BMI, and systolic blood pressure. Thereafter, we performed subgroup analyses by fracture history to examine the difference of the association between BMD scores and FGF21 levels. Statistical analyses were performed using STATA version 12.1 (StataCorp., College Station, TX, USA), and all P values were two-tailed with P values <0.05 being considered significant.
Clinical characteristics
The baseline clinical characteristics of the study subjects were shown in Table 1. Among the 115 postmenopausal women, the mean age was 60.2±7.2 years, and the mean BMI was 24.4±3.5 kg/m2. The mean serum FGF21 concentration was 154±102.5 pg/mL. There were no differences in clinical characteristics between the subjects included in our study and those excluded (data not shown).
Correlation between serum FGF21 level and BMD
In the correlation test, we analyzed the Pearson correlation between log-transformed serum FGF21 level and T-score or regional BMD. Log-transformed serum FGF21 level did not show any significant correlation with the absolute BMD values at all three loci: lumbar, femoral neck, and total femur. Log-transformed serum FGF21 level did not show any significant correlations with osteocalcin (r=−0.088, P=0.350) and C-telopeptide (r=0.036, P=0.704) levels (Fig. 1). The other anthropometric or laboratory values also did not show any significant correlations with FGF21 levels (data not shown). The association between log-transformed serum FGF21 levels and absolute BMD scores was not observed in multivariate analyses, with adjustment for age and BMI (Table 2).
Several studies have shown the beneficial effects of FGF21 on glucose and lipid metabolism [11213]. However, some animal-based studies reported that high levels of circulating FGF21 were associated with a decrease in bone mass by inhibiting osteoblastogenesis by potentiating PPAR-γ activity in bone marrow mesenchymal stem cells [7] or promoting osteoclastogenesis by induction of insulin-like growth factor-binding protein 1 [14]. In FGF21 transgenic mice, decreased BMD was observed, along with increased bone mass with higher markers of bone formation and low markers of bone resorption in FGF21 knockout mice [7]. Originally FGF21 works through FGF receptors and β klotho complex of cell membrane and FGF receptor express in various organs, including growth plate and chondrocyte [1516]; however, there are no studies about FGF receptor on osteoblast or osteoclast so far. The indirect effect of FGF21 through increasing the activity of PPAR-γ is known to be a major mechanism of high bone resorption [7].
To date, few published studies have reported the association between plasma FGF21 level and BMD in humans. One study firstly showed the positive correlation between serum FGF21 level and total BMD and spine BMD only in 16 healthy women with mean age of 34±10 years, but not young men [8]. The authors suggested that the different results observed between men and women was because brown adipose tissue (BAT) secretes FGF21 [17] and BAT was more commonly detected in women and younger individuals than men and older adults [18]. Therefore BAT-secreted FGF21 induced higher FGF21 levels and greater BAT mass resulted in higher BMD [8]. However, the study was limited by its small sample size of only 16 young female adults.
However, a recently published report demonstrated a negative association between serum FGF21 level and Ward's triangle BMD (P=0.022, β=−0.099) only in 119 females, but not in males [10]. In the same study, for the other three regions in BMD areas, there was no significant association neither in males nor females suggesting the minimal role of FGF21 in bone metabolism. On the other hand, an epidemiologic study showed a positive correlation between age and FGF21 [19], suggesting that higher FGF21 levels in the elderly may be associated with lower BMD. However, because our study included only post-menopause women, we could not perform direct comparison of FGF21 level between age groups. Further studies considering age factor are needed.
Recent animal studies showed that intraperitoneal injection of recombinant human FGF21 for 2 weeks did not induce bone loss on DXA in high-fat diet-induced obesity mice [9], suggesting contrasting results with previous findings [78]. A recent human study of a once-weekly synthetic FGF21 analog, PF-05231023, showed that weekly FGF21 administration decreased the levels of N-terminal propeptides of type 1 collagen on day 25, but minimally increased the levels of C-telopeptide cross-linking of type 1 collagen [20]. Our data did not demonstrate any significant association between serum FGF21 level and BMD or bone markers, suggesting the minimal role of FGF21 in bone metabolism.
The major limitation of this study was its cross-sectional design; thus, we could not imply causality from the association between FGF21 and BMD in humans. Second, our study did not have enough study power to assess statistical significance due to small sample size and the weak correlations between FGF21 levels and bone parameters; therefore, our study could not prove that there was no association between them.
In summary, our current study revealed the null or minimal association between serum FGF21 levels and BMD in 115 healthy postmenopausal women. These findings indicate that the recently reported association between high FGF21 levels and bone loss in animal studies may not directly be translated to humans, suggesting the need for further investigations in humans using a large-scale prospective study.
Acknowledgements
This study was supported by a 2017 Research Grant from Kangwon National University (No. 520170423) and a Korean National Research Foundation research grant (NRF-2016R1C1B2011968).

AUTHOR CONTRIBUTIONS: Conception or design: E.H.C., S.W.K. Acquisition, analysis, or interpretation of data: H.S.C., H.A.L. Drafting the work or revising: H.S.C., E.H.C., S.W.K. Final approval of the manuscript: H.S.C., E.H.C.

CONFLICTS OF INTEREST: No potential conflict of interest relevant to this article was reported.

  • 1. Zhang J, Li Y. Fibroblast growth factor 21 analogs for treating metabolic disorders. Front Endocrinol (Lausanne) 2015;6:168. ArticlePubMedPMC
  • 2. Mraz M, Bartlova M, Lacinova Z, Michalsky D, Kasalicky M, Haluzikova D, et al. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol (Oxf) 2009;71:369–375. ArticlePubMed
  • 3. Anuwatmatee S, Tang S, Wu BJ, Rye KA, Ong KL. Fibroblast growth factor 21 in chronic kidney disease. Clin Chim Acta 2017 11 06 [Epub]. Article
  • 4. Lin Z, Wu Z, Yin X, Liu Y, Yan X, Lin S, et al. Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile. PLoS One 2010;5:e15534. ArticlePubMedPMC
  • 5. Yilmaz Y, Eren F, Yonal O, Kurt R, Aktas B, Celikel CA, et al. Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. Eur J Clin Invest 2010;40:887–892. ArticlePubMed
  • 6. Markan KR, Naber MC, Ameka MK, Anderegg MD, Mangelsdorf DJ, Kliewer SA, et al. Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding. Diabetes 2014;63:4057–4063. ArticlePubMedPMC
  • 7. Wei W, Dutchak PA, Wang X, Ding X, Wang X, Bookout AL, et al. Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γ. Proc Natl Acad Sci U S A 2012;109:3143–3148. ArticlePubMedPMC
  • 8. Lee P, Linderman J, Smith S, Brychta RJ, Perron R, Idelson C, et al. Fibroblast growth factor 21 (FGF21) and bone: is there a relationship in humans? Osteoporos Int 2013;24:3053–3057. ArticlePubMedPMCPDF
  • 9. Li X, Stanislaus S, Asuncion F, Niu QT, Chinookoswong N, Villasenor K, et al. FGF21 is not a major mediator for bone homeostasis or metabolic actions of PPARα and PPARγ agonists. J Bone Miner Res 2017;32:834–845. ArticlePubMed
  • 10. Hao RH, Gao JL, Li M, Huang W, Zhu DL, Thynn HN, et al. Association between fibroblast growth factor 21 and bone mineral density in adults. Endocrine 2018;59:296–303. ArticlePubMedPDF
  • 11. Cho EH, Cho KH, Lee HA, Kim SW. High serum osteopontin levels are associated with low bone mineral density in postmenopausal women. J Korean Med Sci 2013;28:1496–1499. ArticlePubMedPMC
  • 12. Laeger T, Baumeier C, Wilhelmi I, Wurfel J, Kamitz A, Schurmann A. FGF21 improves glucose homeostasis in an obese diabetes-prone mouse model independent of body fat changes. Diabetologia 2017;60:2274–2284. ArticlePubMedPMCPDF
  • 13. Gasser E, Moutos CP, Downes M, Evans RM. FGF1: a new weapon to control type 2 diabetes mellitus. Nat Rev Endocrinol 2017;13:599–609. ArticlePubMedPMCPDF
  • 14. Wang X, Wei W, Krzeszinski JY, Wang Y, Wan Y. A liver-bone endocrine relay by IGFBP1 promotes osteoclastogenesis and mediates FGF21-induced bone resorption. Cell Metab 2015;22:811–824. ArticlePubMedPMC
  • 15. Hughes SE. Differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal human adult tissues. J Histochem Cytochem 1997;45:1005–1019. ArticlePubMed
  • 16. Lazarus JE, Hegde A, Andrade AC, Nilsson O, Baron J. Fibroblast growth factor expression in the postnatal growth plate. Bone 2007;40:577–586. ArticlePubMed
  • 17. Fisher FM, Kleiner S, Douris N, Fox EC, Mepani RJ, Verdeguer F, et al. FGF21 regulates PGC-1α and browning of white adipose tissues in adaptive thermogenesis. Genes Dev 2012;26:271–281. ArticlePubMedPMC
  • 18. Lee P, Greenfield JR, Ho KK, Fulham MJ. A critical appraisal of the prevalence and metabolic significance of brown adipose tissue in adult humans. Am J Physiol Endocrinol Metab 2010;299:E601–E606. ArticlePubMed
  • 19. Hanks LJ, Gutierrez OM, Bamman MM, Ashraf A, McCormick KL, Casazza K. Circulating levels of fibroblast growth factor-21 increase with age independently of body composition indices among healthy individuals. J Clin Transl Endocrinol 2015;2:77–82. ArticlePubMedPMC
  • 20. Kim AM, Somayaji VR, Dong JQ, Rolph TP, Weng Y, Chabot JR, et al. Once-weekly administration of a long-acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non-human primates. Diabetes Obes Metab 2017;19:1762–1772. ArticlePubMed
Fig. 1

Correlation analysis between serum fibroblast growth factor 21 (FGF21) levels and osteocalcin (A) and C-telopeptide (B).

enm-33-273-g001.jpg
Table 1

Anthropometric and Laboratory Characteristics

enm-33-273-i001.jpg
Variable Value
No. of cases 115
Age, yr 60.2±7.2
No. of years since menopause 9.4±7.7
BMI, kg/m2 24.4±3.5
SBP, mm Hg 124.1±16.0
DBP, mm Hg 75.9±10.6
FGF21, pg/mL 154.0±102.5
T-score
 Lumbar spine −0.965±1.239
 Femur neck −0.832±0.902
 Total hip −0.407±1.046
BMD, g/cm2
 Spine 0.994±0.149
 Femur neck 0.800±0.108
 Total hip 0.885±0.125
Fracture history
 Whole area 22/112 (19.6)
 Spine 2/113 (1.8)
 Hip 0/113 (0)
Calcium, mg/dL 9.5±0.3
Phosphorous, mg/dL 3.8±0.5
Albumin, mg/dL 4.3±0.3
Creatinine, mg/dL 0.6±0.1
Osteocalcin, ng/mL 12.6±2.8
CTX, ng/mL 0.8±0.4
25-Hydroxyvitamin vitamin D3, ng/mL 6.0±3.3

Values are expressed as mean±SD or number (%).

BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FGF21, fibroblast growth factor 21; BMD, bone mineral density; CTX, C-telopeptide.

Table 2

Association Results of Log-Transformed Serum Fibroblast Growth Factor 21 Levels with Regional BMDs and T-Scores after Adjustment for Age and Body Mass Index

enm-33-273-i002.jpg
Univariate Multivariate
β SE P value β SE P value
BMD
 Lumbar −0.01 0.047 0.837 0.011 0.044 0.795
 Femur neck −0.03 0.034 0.383 −0.007 0.029 0.792
 Femur total −0.023 0.039 0.557 0.003 0.033 0.938
T-score
 Lumbar −0.074 0.391 0.851 0.101 0.364 0.781
 Femur neck −0.25 0.284 0.380 −0.065 0.238 0.786
 Femur total −0.202 0.329 0.541 0.015 0.277 0.956

BMD, bone mineral density; SE, standard error.

Figure & Data

References

    Citations

    Citations to this article as recorded by  
    • FGF-based drug discovery: advances and challenges
      Gaozhi Chen, Lingfeng Chen, Xiaokun Li, Moosa Mohammadi
      Nature Reviews Drug Discovery.2025; 24(5): 335.     CrossRef
    • Effect of Fibroblast Growth Factor (FGF) 19 and 21 on Hip Geometry and Strength in Post-menopausal Osteoporosis (PMO)
      EunJi Kim, Amelia. E. Moore, Dwight Dulnoan, Geeta Hampson
      Calcified Tissue International.2024; 115(5): 562.     CrossRef
    • Fibroblast growth factor 21 and bone homeostasis
      Yan Tang, Mei Zhang
      Biomedical Journal.2023; 46(4): 100548.     CrossRef
    • FGF21 negatively affects long-term female fertility in mice
      Beat Moeckli, Thuy-Vy Pham, Florence Slits, Samuel Latrille, Andrea Peloso, Vaihere Delaune, Graziano Oldani, Stéphanie Lacotte, Christian Toso
      Heliyon.2022; 8(11): e11490.     CrossRef
    • Potential role of fibroblast growth factor 21 in the deterioration of bone quality in impaired glucose tolerance
      D. T. W. Lui, C. H. Lee, V. W. K. Chau, C. H. Y. Fong, K. M. Y. Yeung, J. K. Y. Lam, A. C. H. Lee, W. S. Chow, K. C. B. Tan, Y. C. Woo, K. S. L. Lam
      Journal of Endocrinological Investigation.2021; 44(3): 523.     CrossRef
    • Skeletal Muscle and Bone – Emerging Targets of Fibroblast Growth Factor-21
      Hui Sun, Matthew Sherrier, Hongshuai Li
      Frontiers in Physiology.2021;[Epub]     CrossRef
    • Age‐related bone loss is associated with FGF21 but not IGFBP1 in healthy adults
      Shuen Yee Lee, Kai Deng Fam, Kar Ling Chia, Margaret M. C. Yap, Jorming Goh, Kwee Poo Yeo, Eric P. H. Yap, Sanjay H. Chotirmall, Chin Leong Lim
      Experimental Physiology.2020; 105(4): 622.     CrossRef
    • Chronic Kidney Disease Is Associated with Increased Plasma Levels of Fibroblast Growth Factors 19 and 21
      Małgorzata Marchelek-Myśliwiec, Violetta Dziedziejko, Monika Nowosiad-Magda, Katarzyna Dołęgowska, Barbara Dołęgowska, Andrzej Pawlik, Krzysztof Safranow, Magda Wiśniewska, Joanna Stępniewska, Maciej Domański, Kazimierz  Ciechanowski
      Kidney and Blood Pressure Research.2019; 44(5): 1207.     CrossRef

    • PubReader PubReader
    • ePub LinkePub Link
    • Cite
      Cite
      export Copy Download
      Close
      Download Citation
      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.
      Format:
      • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
      • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
      Include:
      • Citation for the content below
      Association between Serum Fibroblast Growth Factor 21 Levels and Bone Mineral Density in Postmenopausal Women
      Endocrinol Metab. 2018;33(2):273-277.   Published online June 21, 2018
      DOI: https://doi.org/10.3803/EnM.2018.33.2.273
      Close
    • XML DownloadXML Download
    Figure
    • 0
    Association between Serum Fibroblast Growth Factor 21 Levels and Bone Mineral Density in Postmenopausal Women
    Image
    Fig. 1 Correlation analysis between serum fibroblast growth factor 21 (FGF21) levels and osteocalcin (A) and C-telopeptide (B).

    Fig. 1

    Association between Serum Fibroblast Growth Factor 21 Levels and Bone Mineral Density in Postmenopausal Women
    VariableValue
    No. of cases115
    Age, yr60.2±7.2
    No. of years since menopause9.4±7.7
    BMI, kg/m224.4±3.5
    SBP, mm Hg124.1±16.0
    DBP, mm Hg75.9±10.6
    FGF21, pg/mL154.0±102.5
    T-score
     Lumbar spine−0.965±1.239
     Femur neck−0.832±0.902
     Total hip−0.407±1.046
    BMD, g/cm2
     Spine0.994±0.149
     Femur neck0.800±0.108
     Total hip0.885±0.125
    Fracture history
     Whole area22/112 (19.6)
     Spine2/113 (1.8)
     Hip0/113 (0)
    Calcium, mg/dL9.5±0.3
    Phosphorous, mg/dL3.8±0.5
    Albumin, mg/dL4.3±0.3
    Creatinine, mg/dL0.6±0.1
    Osteocalcin, ng/mL12.6±2.8
    CTX, ng/mL0.8±0.4
    25-Hydroxyvitamin vitamin D3, ng/mL6.0±3.3
    UnivariateMultivariate
    βSEP valueβSEP value
    BMD
     Lumbar−0.010.0470.8370.0110.0440.795
     Femur neck−0.030.0340.383−0.0070.0290.792
     Femur total−0.0230.0390.5570.0030.0330.938
    T-score
     Lumbar−0.0740.3910.8510.1010.3640.781
     Femur neck−0.250.2840.380−0.0650.2380.786
     Femur total−0.2020.3290.5410.0150.2770.956
    Table 1 Anthropometric and Laboratory Characteristics

    Values are expressed as mean±SD or number (%).

    BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FGF21, fibroblast growth factor 21; BMD, bone mineral density; CTX, C-telopeptide.

    Table 2 Association Results of Log-Transformed Serum Fibroblast Growth Factor 21 Levels with Regional BMDs and T-Scores after Adjustment for Age and Body Mass Index

    BMD, bone mineral density; SE, standard error.

    Table 1

    Table 2

    Endocrinol Metab : Endocrinology and Metabolism
    © Korean Endocrine Society.
    TOP